Clinical trial · Observational
Collection of Circulating Biomarkers in Pancreatic Cancer
Protocol to Permit Collection of Circulating Biomarkers in Pancreatic Cancer
NCT05743049CI-TRIAL-00107449recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Obtaining blood for analysis of various circulating biomarkers | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Blood specimens
- description
- Collection of blood for analysis of various circulating biomarkers in patients with pancreatic adenocarcinoma.
- interventionNames
- Other: Obtaining blood for analysis of various circulating biomarkers
Primary outcomes (1)
- measure
- To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use.
- timeFrame
- Through study completion, an average of 1 year
Secondary outcomes (2)
- measure
- To create a computerized clinical data set from subjects with pancreatic cancer that contains information related to the subject's general health, disease status, treatments, and response.
- timeFrame
- Through study completion, an average of 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * The subject must have a known or presumed diagnosis of pancreatic adenocarcinoma * The subject must be a patient of the University of Pennsylvania * The subject must be able to provide informed consent * The subject must be 18 years of age or older Exclusion Criteria: . Subjects who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.
References
Publications (0)
Data not yet available
No reference posted for this study.